<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                               Amendment No. 1 to
                                  FORM 10-QSB/A

(Mark One)

[X]      Quarterly Report Pursuant to Section 13 or 15(d) of The Securities
         Exchange Act of 1934

For the quarterly period ended:  November 30, 2003

                                       Or

[ ]      Transition Report Pursuant to Section 13 or 15(d) of the Securities
         Exchange Act of 1934

                        Commission file number: 000-32249

                             MIV THERAPEUTICS, INC.
                             ----------------------
        (Exact name of small business issuer as specified in its charter)

          Nevada                                             n/a
(State or other jurisdiction of                (IRS Employee Identification No.)
incorporation or organization)

               1-8765 Ash Street, Vancouver, B.C., Canada, V6P 6T3
                    (Address of principal executive offices)

                                 (604) 301-9545
                           (Issuer's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant is an accelerated filer (as
defined by Rule 12b-2 of the Exchange Act Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date:

Common Stock, $0.001 par value                         36,413,148
          (Class)                          (Outstanding as of November 30, 2003)



<PAGE>


                             MIV THERAPEUTICS, INC.
                                   FORM 10-QSB
                                      INDEX

                                                                            Page
                                                                            ----
Part I - FINANCIAL INFORMATION

Item 1.  Financial Statements (Unaudited)

Consolidated Balance Sheets.................................................F-1

Consolidated Statement of Operations........................................F-2

Consolidated Statement of Cash Flows........................................F-3

Notes to Consolidated Financial Information.................................F-4

Item 2   Management's Discussion and Analysis or Plan of Operation............3

Item 3   Quantitative and Qualitative Disclosure About Market Risk............7

Item 4   Controls and Procedures.............................................11

Part II  OTHER INFORMATION

Item 1   Legal Proceedings...................................................11

Item 2   Changes in Securities and Use of Proceeds...........................11

Item 3   Defaults Upon Senior Securities.....................................12

Item 4   Submission of Matters to a Vote of Security Holders.................12

Item 5   Other Information...................................................12

Item 6   Exhibits and Reports on Form 8-K....................................12

Signatures...................................................................13

Certifications...............................................................14


                                       2
<PAGE>

                          PART I: FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS (UNAUDITED)
<TABLE>

                               MIV THERAPEUTICS, INC. AND SUBSIDIARIES
                                    (A DEVELOPMENT STAGE COMPANY)

                                 CONDENSED CONSOLIDATED BALANCE SHEET
                                             (UNAUDITED)
<CAPTION>

                                                                         NOVEMBER 30       MAY 31
                                                                            2003            2003
-----------------------------------------------------------------------------------------------------
<S>                                                                     <C>             <C>
                                   ASSETS
CURRENT
     Cash and cash equivalents                                          $         --    $     11,614
     Prepaid expenses and deposits                                           330,489          46,819
     Other receivable                                                        165,947         165,485
                                                                        -----------------------------
                                                                             496,436         223,918
INVESTMENT, at cost                                                           50,000          50,000
PLANT AND EQUIPMENT, net                                                     243,851         312,179
                                                                        -----------------------------

                                                                        $    790,287    $    586,097
=====================================================================================================

                                LIABILITIES
CURRENT
     Accounts payable                                                   $    379,585    $    448,959
     Due to related parties                                                  168,407         136,983
                                                                        -----------------------------
                                                                             547,992         585,942
LOAN PAYABLE                                                                 500,000         500,000
                                                                        -----------------------------
                                                                           1,047,992       1,085,942
                                                                        -----------------------------

STOCKHOLDERS' DEFICIENCY

CAPITAL STOCK
     Authorized:
         80,000,000 common shares with a par value of $0.001
         20,000,000 preferred shares with a par value of $0.001
     Issued and outstanding:
         30,413,148 common shares at November 30, 2003 and 24,577,047
         common shares at May 31, 2003
                                                                              30,413          24,577

ADDITIONAL PAID-IN CAPITAL                                                12,003,490       9,403,308
WARRANTS                                                                   2,032,202       2,093,760
DEFERRED COMPENSATION                                                       (575,795)        (48,649)
COMMON STOCK ISSUABLE                                                         24,994          31,244
DEFICIT ACCUMULATED DURING THE DEVELOPMENT STAGE                         (13,716,406)    (11,952,336)
ACCUMULATED OTHER COMPREHENSIVE INCOME                                       (56,603)        (51,749)
                                                                        -----------------------------
                                                                            (257,705)       (499,845)
                                                                        -----------------------------

                                                                        $    790,287    $    586,097
=====================================================================================================

              See accompanying notes to the condensed consolidated financial statements


                                                 F-1
</TABLE>
<PAGE>
<TABLE>

                                    MIV THERAPEUTICS, INC. AND SUBSIDIARIES
                                         (A DEVELOPMENT STAGE COMPANY)

                                CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
                                                  (UNAUDITED)
<CAPTION>

                                                                                                  PERIOD FROM
                                                                                                  INCORPORATION
                                                                                                   JANUARY 20
                                       THREE MONTHS ENDED               SIX MONTHS ENDED            1999 TO
                                           NOVEMBER 30                     NOVEMBER 30             NOVEMBER 30
                                      2003            2002            2003            2002            2003
---------------------------------------------------------------------------------------------------------------
<S>                               <C>             <C>             <C>             <C>             <C>
EXPENSES
     General and administrative   $    477,670    $    397,123    $    983,136    $    659,748    $  6,476,313
     Stock based compensation*              --         469,425              --         666,154       3,426,665
     Research and development          100,241         175,798         241,213         235,716       2,930,749
     Depreciation                       37,088          37,585          72,693          75,466         504,199
     Interest expense                    3,800             552          11,234          16,029         887,041
     Licenses acquired charged
       to operations                        --              --              --         150,000         479,780
                                  -----------------------------------------------------------------------------

LOSS FROM OPERATIONS                  (618,799)     (1,080,483)     (1,308,276)     (1,803,113)    (14,704,747)

LOSS ON FOREIGN EXCHANGE               (16,220)             --         (16,308)             --         (27,428)

INTEREST INCOME                             --              --              --              --          49,767
                                  -----------------------------------------------------------------------------

LOSS FOR THE PERIOD BEFORE
  MINORITY INTEREST                   (635,019)     (1,080,483)     (1,324,584)     (1,803,113)    (14,682,408)

LESS: MINORITY INTEREST SHARE
  OF LOSS                                   --              --              --              --       1,224,308
                                  -----------------------------------------------------------------------------

NET LOSS FOR THE PERIOD           $   (635,019)   $ (1,080,483)   $ (1,324,584)   $ (1,803,113)   $(13,458,100)
===============================================================================================================

BASIC AND FULLY DILUTED LOSS
  PER SHARE                       $      (0.02)   $      (0.06)   $      (0.05)   $      (0.10)
===============================================================================================

WEIGHTED AVERAGE NUMBER OF
  COMMON SHARES OUTSTANDING         28,960,508      18,256,119      28,124,259      17,463,267


COMPREHENSIVE LOSS
     Net loss for the period      $   (635,019)   $ (1,080,483)   $ (1,324,584)   $ (1,803,113)
     Foreign currency
       translation adjustment           (2,613)          9,601          (4,854)         83,995
                                  -------------------------------------------------------------
TOTAL COMPREHENSIVE LOSS          $   (637,632)   $ (1,070,882)   $ (1,329,438)   $ (1,719,118)
===============================================================================================

*Note:   Stock based compensation represents the fair value of stock options
         granted to consultants and the calculation of the "fair value" at the
         date of grant is more fully disclosed in Note 2.

                   See accompanying notes to the condensed consolidated financial statements

                                                      F-2
</TABLE>
<PAGE>
<TABLE>

                                  MIV THERAPEUTICS, INC. AND SUBSIDIARIES
                                       (A DEVELOPMENT STAGE COMPANY)

                              CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
                                                (UNAUDITED)
<CAPTION>

                                                                                            PERIOD FROM
                                                                                           INCORPORATION
                                                                                            JANUARY 20
                                                                 SIX MONTHS ENDED             1999 TO
                                                                    NOVEMBER 30             NOVEMBER 30
                                                                2003            2002            2003
---------------------------------------------------------------------------------------------------------
<S>                                                         <C>             <C>             <C>
CASH FLOWS FROM OPERATING ACTIVITIES
     Loss for the period                                    $ (1,324,584)   $ (1,803,113)   $(14,682,408)

     Adjustments to reconcile loss to net cash used in
       operating activities
         Stock based compensation                                     --         666,154       3,426,665
         Stock issued for other than cash                        644,085              --       2,667,477
         Interest expense on related party loan                       --              --         850,000
         Depreciation                                             72,693          75,466         504,199
         Leasehold improvements written down                          --              --          13,300
         Intangible asset impairment                                  --         150,000         150,000

     Changes in non-cash working capital items:
         Other receivable                                           (462)            477        (166,103)
         Prepaid expenses and deposits                          (253,312)         (3,247)       (300,810)
         Accounts payable and accrued liabilities                (69,373)        291,526         404,203
                                                            ---------------------------------------------
                                                                (930,953)       (622,737)     (7,133,477)
                                                            ---------------------------------------------

CASH FLOWS FROM FINANCING ACTIVITIES
     Issuance of common stock and warrants for cash, less
       share issuance costs                                      872,141              --       5,423,042
     Due to related parties                                       31,424              --       1,018,407
     Cash acquired in reverse acquisition                             --              --          13,824
     Loan payable                                                     --              --         500,000
     Common stock redemption                                          --              --        (120,000)
     Subscriptions received                                       24,994         577,506       1,382,304
                                                            ---------------------------------------------
                                                                 928,559         577,506       8,217,577
                                                            ---------------------------------------------

CASH FLOWS FROM INVESTING ACTIVITIES
     Acquisition of license                                           --              --        (200,000)
     Purchases of plant and equipment                             (1,819)        (35,075)       (763,722)
                                                            ---------------------------------------------
                                                                  (1,819)        (35,075)       (963,722)
                                                            ---------------------------------------------

FOREIGN EXCHANGE EFFECT ON CASH                                   (7,401)         83,995        (120,378)
                                                            ---------------------------------------------

NET INCREASE IN CASH AND CASH EQUIVALENTS                         11,614           3,689              --

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD                    11,614           4,536              --
                                                            ---------------------------------------------

CASH AND CASH EQUIVALENTS, END OF PERIOD                    $         --    $      8,225    $         --
=========================================================================================================


                See accompanying notes to the condensed consolidated financial statements

                                                   F-3
</TABLE>

<PAGE>

                     MIV THERAPEUTICS, INC. AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)

           CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Continued)
                                   (UNAUDITED)



SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:

During the period ended November 30, 2003, the Company issued:

a)       40,000 shares and warrants for finders fee at a value of $12,000;

b)       959,185 common shares at a value of $414,571 for compensation expense
         pursuant to the "2003 Non-Qualified Stock Compensation Plan".

During the period ended November 30, 2002, the Company issued:

a)       957,606 common shares for settlement of accounts payable and accrued
         liabilities totalling $356,421;

b)       79,641 common shares at a value of $27,078 for compensation expense
         pursuant to the "2002 Non-Qualified Stock Compensation Plan";

c)       2,042,688 shares and warrants at a value of $815,090 for subscriptions
         received, of which $62,495 was received during the quarter ended
         November 30, 2002.







                                       F-4

<PAGE>


                     MIV THERAPEUTICS, INC. AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)

               NOTE TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

                                NOVEMBER 30, 2003
                                   (UNAUDITED)



1.   BASIS OF PRESENTATION

     The accompanying unaudited condensed consolidated financial statements have
     been prepared by the Company pursuant to the rules and regulations of the
     Securities and Exchange Commission ("SEC") and, in the opinion of
     management, include all adjustments (consisting of normal recurring
     accruals) necessary for fair presentation of financial position, results of
     operations and cash flows for the interim periods. Certain information and
     footnote disclosures normally included in financial statements prepared in
     accordance with generally accepted accounting principles have been
     condensed or omitted pursuant to the rules and regulations of the SEC. The
     Company believes that the disclosures contained herein are adequate to make
     the information presented not misleading. The statements of operations for
     the six months ended November 30, 2003 are not necessarily indicative of
     the results to be expected for the full year. These unaudited condensed
     consolidated financial statements should be read in conjunction with the
     audited financial statements and accompanying notes included in the
     Company's 2003 Annual Report on Form 10-K for the year ended May 31, 2003.

     The condensed consolidated financial statements have been prepared on a
     going concern basis, which contemplated the realization of assets and
     satisfaction of liabilities in the normal course of business. Recurring
     losses from operations and operating cash constraints are potential
     factors, which, among others, may indicate that the Company will be unable
     to continue as a going concern for a reasonable period of time. The
     independent auditors' report on the May 31, 2003 financial statements
     stated the Company's "dependence on outside financing, lack of sufficient
     working capital and continuing losses from operations raise substantial
     doubt about the Company's ability to continue as a going concern". These
     factors, among others, raise substantial doubt about the Company's ability
     to continue as a going concern. The financial statements do not include any
     adjustments that might result from the outcome of this uncertainty.

     The financial statements do not include adjustments relating to
     recoverability and classification of recorded assets amounts, or the
     amounts and classification of liabilities that might be necessary should
     the Company be unable to continue as a going concern. The Company's ability
     to continue as a going concern is dependent upon its ability to generate
     sufficient cash flow to meet its obligations on a timely basis and,
     ultimately, to attain profitable operations.





                                       F-5
<PAGE>

                     MIV THERAPEUTICS, INC. AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)

               NOTE TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

                                NOVEMBER 30, 2003
                                   (UNAUDITED)


2.   STOCK BASED COMPENSATION

     The Company accounts for employee stock based compensation using the
     intrinsic value method prescribed in Accounting Principles Board Opinion
     No. 25 - "Accounting for Stock Issued to Employees", and related
     interpretations. Accordingly, compensation cost for stock options is
     measured as the excess, if any, of the fair value of the Company's common
     stock at the date of the grant over the amount an employee must pay to
     acquire the common stock. Non-employee stock based compensation is
     accounted for using the fair value method in accordance with SFAS No. 123 -
     "Accounting for Stock Based Compensation".

     During the period, the Company issued an aggregate of 1,740,098 common
     shares and an aggregate of 2,250,000 warrants for consulting services
     rendered and to be rendered at a value of $1,225,590. Accordingly, $478,853
     was charged to operations during the six month period ended November 30,
     2003, and $746,737 was recorded as deferred compensation.

     The following illustrates the effect on net loss and net loss per share if
     the Company had accounted for stock option granted using the fair value
     method:
<TABLE>
<CAPTION>
                                                               2003           2002
                                                           ------------   ------------
<S>                                                        <C>            <C>
    Net loss - as reported                                 $(1,324,584)   $(1,803,113)

    Add:  Stock-based compensation expense included
          in net loss - as reported                                 --        666,154

    Loss: Stock-based compensation expense determined
          under fair value method                                   --       (703,268)
                                                           ------------   ------------

    Net loss - pro forma                                   $(1,324,584)   $(1,840,227)
                                                           ============   ============

    Net loss per share (basic and diluted) - as reported   $     (0.05)   $     (0.10)
    Net loss per share (basic and diluted) - pro forma     $     (0.05)   $     (0.11)
</TABLE>

3.   INVESTMENT

     The Company's investment comprises 1,000,000 Class A common shares of
     Endovasc Ltd. Inc., and is pledged as security of the loan payable due on
     December 30, 2005.

     The investment was disposed of subsequent to November 30, 2003 as a result
     of the default on the loan interest payment due June 2, 2003 (Note 4).



                                       F-6

<PAGE>


                     MIV THERAPEUTICS, INC. AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)

               NOTE TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

                                NOVEMBER 30, 2003
                                   (UNAUDITED)



4.   LOAN PAYABLE

     THE LOAN PAYABLE IS SECURED BY THE INVESTMENT IN 1,000,000 CLASS A COMMON
     SHARES OF ENDOVASC LTD. INC. THE LOAN IS REPAYABLE ON DECEMBER 30, 2005,
     BEARING INTEREST PER ANNUM EQUAL TO THE LONDON INTERBANK OFFERED RATE PLUS
     1%. INTEREST IS PAYABLE SEMI-ANNUALLY COMMENCING ON JUNE 2, 2003.


5.   RELATED PARTY TRANSACTIONS

     a)  During the three month period ended November 30, 2003, the Company paid
         $59,086 (2002 - $51,024) in management fees to directors of the
         Company. At November 30, 2003 $168,407 (2002 - $63,514) is payable to
         the Chief Executive Officer of the Company for accrued salary and
         expenses paid on behalf of the Company, of which $99,500 is secured by
         the assets of the Company.

     b)  During the three month period ended November 30, 2003, the Company
         issued 5,475 (2002 - 52,941) common shares at a value of $2,190 (2002 -
         $18,000) to a director of the Company for compensation expense.


6.   CAPITAL STOCK

     The Company issued 6,000,000 common shares to a financial custodian acting
     as trustee pursuant to a listing of the Company's shares on the Frankfurt
     Stock Exchange. The Company is conducting a Regulation S Offering through
     the facilities of the Berlin Stock Exchange to raise capital in mainly
     German speaking countries. Up to a maximum of 10,000,000 Regulation S
     shares of the Company will be offered through the Exchange at a price of
     $0.50 to non-U.S. persons only. The trustee will receive a fee of 3% of the
     total value of the shares held in trust to be paid in equal instalments of
     30,000 common shares per month over a ten month period, assuming the
     maximum offering is sold. The shares may only be traded on German stock
     exchanges pursuant to Regulation S.


7.   SUBSEQUENT EVENTS

     a)  Subsequent to November 30, 2003, the Company issued 15,400 common
         shares to a director of the Company for services rendered at a value of
         $6,309.




                                       F-7

<PAGE>


                     MIV THERAPEUTICS, INC. AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)

               NOTE TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

                                NOVEMBER 30, 2003
                                   (UNAUDITED)



7. SUBSEQUENT EVENTS (Continued)

     b)  The Company failed to make the interest payment due June 2, 2003. As at
         June 12, 2003, the loan balance together with accrued interest was in
         default. Upon default, the lender is entitled to realize on the
         security and, on January 8, 2004, a court order was obtained confirming
         that the indebtedness of the Company was extinguished. Subsequent to
         the quarter end, the Company will record an extraordinary gain of
         $457,601 on the extinguishment of the debt and accrued interest, net of
         the cost of the pledged investment of $50,000.



                                       F-8

<PAGE>


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS

The following discussion contains forward-looking statements that are subject to
significant risks and uncertainties. There are several important factors that
could cause actual results to differ materially from historical results and
percentages and results anticipated by the forward-looking statements. The
Company has sought to identify the most significant risks to its business, but
cannot predict whether or to what extent any of such risks may be realized nor
can there be any assurance that the Company has identified all possible risks
that might arise. Investors should carefully consider all of such risks before
making an investment decision with respect to the Company's stock. In
particular, investors should refer to the section entitled, "Factors that May
Affect Future Results and Market Price of Stock".

Plan of Operations
------------------

The Company is developing and has acquired a family of medical device
technologies that form the basis of its product development programs. The
Company's proprietary products are derived from its expertise in minimally
invasive implantable devices and from a series of licensed technologies for
novel coating and drug delivery technologies.

The Company's core technologies are the basis for the following products that
are in various stages of commercial development:

     1. Laser-cut coronary stent - in manufacturing
     2. Biocompatible coating for stents and drug delivery applications - in
        pre-clinical development

In addition, the Company intends to use its proprietary coating and
drug-delivery technologies, along with the biodegradable stent technology, to
develop a series of drug-delivery devices that offer the benefits of local,
sustained delivery of therapeutic agents from a biodegradable platform. The
combination of these features would position MIV Therapeutics as a leader in the
rapidly growing drug delivery sector.

Over the next 2-3 years, the Company intends to expand the volume of
manufacturing of its existing laser-cut stent through private-label agreements
and distribution agreements, targeting markets in countries where a
cost-effective coronary stent would be a competitive product. During this same
timeframe, the Company intends to complete development and obtain a CE mark for
its biocompatible coated stents, which can then be marketed internationally
through agreements with major medical device marketing partners. The initial
focus will be on coated stents for use in angioplasty procedures, where a
biocompatible product is required to prevent the development of restenosis.

                                       3
<PAGE>

In addition, MIVT previously established a joint venture with Endovasc to
develop a novel biodegradable stent technology that offers the potential for the
commercial development of resorbable medical devices for local drug delivery
applications as well as an ANGIOGENIX(TM) drug coating for stents. The Company
intended to advance this proprietary technology through to commercial
development and utilize it as the basis for a range of drug delivery products
for both coronary and other applications. However, the company is currently
focused on its hyroxyapetite coatings more than any other projects.

After completing development of these products, MIVT will have successfully
transitioned itself from being a manufacturer of coronary stents, into an
innovative drug-delivery company with proprietary technologies that can be
applied to a wide range of therapeutic applications for the delivery of a
variety of pharmaceutical agents.

DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

The Company has incurred annual operating losses since its inception in January
1999 related primarily to the research and clinical development of its
technologies and products, and general administration costs. During the quarter
ended November 30, 2003, the Company posted a loss of $635,019, compared to a
loss of $1,080,483 for the three months ended November 30, 2002.

The working capital deficit decreased from a deficit of $574,826 (November 30,
2002) to a deficit of $51,556 (November 30, 2003) the decrease in the working
capital deficit is due primarily to decreases in accounts payable, accrued
liabilities, and prepaid expenses.

The Company's main focus during the three months ending November 30, 2003 has
been the continued research and development of new therapeutic technologies and
its biocompatible coating for stent and drug delivery systems. During this
period of time, the Company initiated the transfer of technology from the
University of British Columbia to its company owned premises with focus on the
introduction of proper process controls and volume production. This transition
was facilitated through the acquisition of sophisticated measuring and
processing equipment.

General & Administrative Expenses
---------------------------------

General and administrative expenses increased to $477,670 during the quarter
ended November 30, 2003, compared to $397,123 for the quarter ended November 30,
2002. The increase in 2003 is mainly due to increased operations and need for
additional support services.

Research & Development Expenses
-------------------------------

Research and developmental costs decreased during the quarter ended November 30,
2003 to $100,241 compared to $175,798 for the quarter ended November 30, 2002.
The decrease in 2003 resulted primarily from government research grants for
research and development related to animal trials on its coating technology.


                                       4
<PAGE>

Depreciation Expense
--------------------

Depreciation expenses remained fairly constant at $37,088 during the quarter
ended November 30, 2003 compared to $37,585 for the quarter ended November 30,
2002.

Liquidity And Capital Resources
-------------------------------

Since inception, the Company has financed its operations from private financing,
the exercise of warrants and interest income. The company has suffered recurring
losses from operations and has a working capital deficiency of $51,556 (current
assets less current liabilities), which raises substantial doubt about its
ability to continue as a going concern.

Stock based compensation decreased for the quarter ended November 30, 2003, to
$0 compared to stock based compensation of $469,425 during the same period in
2002.

Financing
---------

The Company's capital requirements have been and will continue to be
significant. As of November 30, 2003, the Company had a working capital
deficiency of $51,556.

Cash flow from financing activities increased to $928,559 compared to $577,506
for the same period in 2002.

The financing activities included private placement stock subscriptions
totalling $24,994 and issuances of warrants and common shares for cash totaling
$872,141.

Warrants
--------

As at November 30, 2003, the Company has outstanding warrants to purchase
13,497,615 common shares.

The following table summarizes information about the warrants issued by the
Company:

                                                    Number of
Quarter ended November 30, 2003                     underlying shares
-------------------------------                     -----------------

Warrants outstanding - August 31, 2003                  11,465,615
Warrants issued                                          2,032,202
Warrants expired                                                 0
Balance, end of period - November 30, 2003              13,497,615



                                       5
<PAGE>


Stock-based compensation
------------------------

Under the Company's 2001 Stock Option Compensation Plan, a total of 5,000,000
options may be granted. The Company has granted these incentive stock options to
employees, consultants, officers and directors of the Company.

At November 30, 2003, the Company had 4,175,000 options outstanding. During the
three months ended November 30, 2003, the Company did not grant any options and
no options lapsed.

The following table summarizes information about the stock options issued by the
Company:

                                             Number of         Weighted Average
Quarter ended November 30, 2003              Options           Exercise Price
-------------------------------              -------           --------------

Options outstanding - August 31, 2003       4,175,000              $0.84
Options issued                                      0
Options cancelled                                   0
Balance, end of period - November 30, 2003  4,175,000              $0.84

Cash Position
-------------

At November 30, 2003, the Company had cash and cash equivalents of $0 compared
to a cash position of $8,225 at November 30, 2002. The decrease in the Company's
cash position is due primarily to an increase in the scope of the Company's
operations.

The company intends to raise additional funds through equity financings via
private placements, as it may need to raise additional capital to fund
operations over the long-term. There can be no guarantee that such funds will be
available to the Company.

Accounts Payable & Accrued Liabilities
--------------------------------------

Accounts payable and accrued liabilities decreased in the quarter ended November
30, 2003 to $379,585 compared to $771,663 at November 30, 2002. The majority of
this decrease is attributed to improved operating efficiencies.

Cash requirements and need for additional funds
-----------------------------------------------

To date, the Company has invested approximately US$10 million in the development
of its stent products, coatings and operations establishing a quality
manufacturing facility and completing laboratory and preclinical testing on its
stent coatings. The Company also has developed strong research collaborations
with the University of British Columbia for its proprietary stent coatings and
has implemented an aggressive in-house product development program.


                                       6
<PAGE>

In order to commercialize its HAp coating technologies, and to initiate
marketing efforts for its laser-cut stent, the Company will require
approximately US$5 million in the coming year. These funds could be provided
through any combination of the exercise of existing warrants and options and/or
through subsequent rounds of financing.

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

The business of the Company involves a number of risks and uncertainties that
could cause actual results to differ materially from results projected in any
forward-looking statement, or statements, made in this report. These risks and
uncertainties include, but are not necessarily limited to the risks set forth
below. The Company's securities are speculative and investment in the Company's
securities involves a high degree of risk and the possibility that the investor
will suffer the loss of the entire amount invested.

DEVELOPMENT STAGE COMPANY

The Company is in the development stage and currently has no products approved
for sale or use. The Company will not be able to sell significant quantities of
its products until such time, if ever, as it receives regulatory approval to
commercially market such products, and thus the Company's long-term viability,
growth, and profitability will depend upon successful testing, approval, and
commercialization of the MIVI Stent or other products resulting from its
research and development activities. Adverse or inconclusive results in clinical
trials of these products could significantly delay or ultimately preclude any
regulatory approvals, and even if obtained there can be no assurance that any
product approval would lead to the successful commercialization of the product
approved. Furthermore, the Company does not expect to begin the regulatory
approval process in the United States for at least the next three years, and
will only pursue approval and marketing of its products in the countries
recognizing the CE Mark, such as most European and Asian countries.

LIMITED OPERATION HISTORY.

The Company has a limited operating history upon which an evaluation of its
prospects can be made. There can be no assurance that the Company will
effectively execute MIV's business plan or manage any growth of the MIV
business, or that the Company's future operating and financial forecast will be
met. Future development and operating results will depend on many factors,
including access to adequate capital, the completion and regulatory approval of
marketable products, the demand for the Company's products, the level of product
and price competition, the Company's success in setting up and expanding
distribution channels, and whether the Company can control costs. Many of these
factors are beyond the control of the Company. In addition, the Company's future
prospects must be considered in light of the risks, expenses, and difficulties
frequently encountered in establishing a new business in the medical device
industry, which is characterized by intense competition, rapid technological
change, highly litigious competitors, potential product liability and
significant regulation.


                                       7
<PAGE>

HISTORY OF LOSSES, ANTICIPATED FUTURE LOSSES.

Since inception, the Company has suffered recurring losses. The Company has
funded its operations through the issuance of common stock, and through related
party loans since inception, in order to meet its strategic objectives. The
Company anticipates that losses will continue until such time, if ever, as the
Company is able to generate sufficient revenues to support its operations. The
Company's ability to generate revenue primarily depends on its success in
completing development and obtaining regulatory approvals for the commercial
sale of the products under development. There can be no assurance that any such
events will occur, that the Company will attain revenues from commercialization
of its products, or that the Company will ever achieve profitable operations.

UNPREDICTABILITY OF REVENUES.

The life cycle of the products that the Company plans to develop is difficult to
predict. Failure to gain timely market acceptance of its products would have a
material adverse effect on the Company's ability to generate revenue, and would
have a material adverse effect on the Company's business, financial condition
and results of operations. To successfully gain market acceptance, the Company
must develop the ability to manufacture its products in large quantities in
compliance with regulatory requirements and at an acceptable cost. The Company
has no long-term experience in manufacturing stent products, and could
experience difficulties in development or manufacturing that may have a material
adverse effect on the Company's ability to market its product. Moreover, there
can be no assurance that the Company will be successful in scaling up
manufacturing operations sufficient to produce its products in sufficient volume
to generate market acceptance.

COMPETITION AND MARKET FACTORS.

The market in which the Company intends to operate is dominated by several large
firms with established products, and the Company's success is dependant upon
acceptance of its products by the medical community as reliable, safe and
cost-effective. It may be difficult or impossible for the Company to achieve
such acceptance of its products in view of these market conditions. In addition,
the Company's competitors are more financially stable than the Company and have
significant resources for research and development available to them. Thus it is
likely that they will be quicker to market than the Company, with products that
will compete with its products, should it be successfully approved and
commercialized. Moreover, even if the Company successfully brings its products
to market ahead of its projected competitors, established competitors could
quickly bring products to market that would compete. In addition, the medical
device market is subject to constant introduction of new products and designs.
Market acceptance of the Company's products may be influenced by new products or
technologies that come to market, which could render the Company's products
obsolete or prohibitively expensive.


                                       8
<PAGE>

DEPENDENCE ON FINANCING.

The Company's capital requirements have been and will continue to be
significant. The Company will be dependant on future financing to fund its
research and development as well as other working capital requirements. The
Company estimates that its current working capital will support its activities
for no more than four months. After that time, the Company will need additional
financing. The Company is currently anticipating further subscriptions for its
common stock, but there can be no assurance that these subscriptions will be
forthcoming or that they will result in sufficient capital for the Company to
meet its current and expected working capital needs. It is not anticipated that
any of the officers, directors or current shareholders of the Company will
provide any significant portion of the Company's future financing requirements.
Furthermore, in the event that the Company's plans change, its assumptions
change or prove inaccurate, or its capital resources prove to be insufficient to
fund operations, the Company could be required to seek additional financing
sooner than currently anticipated, or in greater amounts than is currently
anticipated. Any inability to obtain additional financing when needed would have
a material adverse effect on the Company, including possibly requiring the
Company to significantly curtail or possibly cease its operations. In addition,
any future equity financing may involve substantial dilution to the Company's
existing shareholders.

DEPENDENCE MANAGEMENT AND RECRUITING.

The Company currently has 6 full time employees and only three full-time
officers and directors. In addition, the Company has entered into consulting
agreements with three individuals two of whom are also a Directors, to provide
management services to the Company. The remainder of the Company's management
has been undertaken by independent consultants. This may make it difficult for
the Company to attract capital investment sufficient to meet its capital needs.
Because the Company is in the development stage and has not yet produced a
marketable product, it will be reliant upon its ability to attract skilled
members of the Stent or medical products industries. There can be no assurance
that the Company will be able to identify suitable candidates for employment, or
to attract them to the Company should they be identified. In addition, the
Company will be heavily dependent upon creative design and engineering skills of
individuals with whom it has little familiarity, and who may not perform as
expected.

INTELLECTUAL PROPERTY RISKS.

The Company's success will depend in part on whether the Company can obtain
patent protection for its products and processes, preserve trade secrets and
proprietary technology, and operate without infringing upon patent or other
proprietary rights of third parties. The Company has patent applications pending
in the United States and in several foreign markets, and is in the process of
filing additional foreign patent applications, but there can be no assurance
that any of these patents will be issued or that patents will not be challenged.
A significant number of medical device companies, other companies, universities,
and research institutions have filed patent applications or have been issued
patents relating to stents and stent delivery systems, and there has been
substantial litigation in this area. Established companies in the medical
products industry generally, and the stent industry in particular, are
aggressive in attempts to block new entrants to their markets, and the Company's
products, if successfully developed, may interfere with the intellectual
property rights of these companies. The Company's success will depend on its
products not infringing patents that the Company expects would be vigorously
prosecuted.


                                       9
<PAGE>

Furthermore, the validity and breadth of claims in medical technology patents
involve complex legal and factual questions and, therefore, are highly
uncertain. Even if the Company successfully patents the MIVI laser-cut stent,
there can be no assurance that it would be able to successfully assert its
patents against competing products. In addition, infringement claims against the
MIVI laser-cut stent could be sufficiently expensive to have a material adverse
effect on the Company's results or ability to continue marketing its products.

PRODUCT LIABILITY EXPOSURE.

The Company's business exposes it to potential product liability risks, which
are inherent in the testing, manufacturing, marketing and sale of medical
products. While the Company will take precautions it deems to be appropriate to
avoid product liability suits against it, there can be no assurance that it will
be able to avoid significant product liability exposure. Product liability
insurance for the medical products industry is generally expensive, to the
extent it is available at all. The Company has not yet sought to obtain product
liability coverage. The Company intends to obtain such coverage when it is
apparent that the MIVI Stent or other products developed by the Company will be
marketable. There can be no assurance that it will be able to obtain such
coverage on acceptable terms, or that any insurance policy will provide adequate
protection against potential claims. A successful product liability claim
brought against the Company may exceed any insurance coverage secured by the
Company, and could have a material adverse effect on the Company's results or
ability to continue marketing its products.

UNCERTAINTY OF HEALTHCARE REIMBURSEMENT.

The health care industry is subject to changing political, economic and
regulatory influences that may affect the procurement practices and operations
of healthcare industry participants. During the past several years, government
regulation of the healthcare industry has changed significantly in several
countries. Healthcare industry participants may react to new policies by
curtailing or deferring use of new treatments for disease, including treatments
that would use the products that the Company intends to develop. This could
substantially impair the Company's ability to successfully commercialize the
MIVI Stent, which would have a material adverse effect on the Company's
performance.

PENNY STOCK RULE.

The Company's common stock is listed on the OTCBB. Investors may find it more
difficult to dispose of, or to obtain accurate quotations as to the market value
of, the Company's common stock than would otherwise be the case were the
Company's common stock listed on a more recognized stock exchange or quotation
service. In addition, trading in the Company's common stock is currently subject
to certain rules under the Exchange Act, which require additional disclosure by
broker-dealers in connection with any trades involving a stock defined as a
"penny stock." Penny stocks are generally non-Nasdaq equity securities with a
market price less than $5.00 per share. The penny stock rules require
broker-dealers selling penny stocks to make certain disclosures about such
stocks to purchasers thereof, and impose sales practice restrictions on
broker-dealers in certain penny stock transactions. The additional burdens
imposed upon broker-dealers by these rules may discourage them from effecting
transactions in the Company's common stock, which could limit the liquidity of
the common stock and the ability of the Company's stockholders to sell their
stock in the secondary market.


                                       10
<PAGE>

ITEM 4. CONTROLS AND PROCEDURES

The registrant's Principal executive officers and principal financial officer,
based on their evaluation of the registrant's disclosure controls and procedures
(as defined in Rules 13a-14 ( c ) of the Securities Exchange Act of 1934) as of
August 31, 2003 have concluded that the registrants' disclosure controls and
procedures are adequate and effective to ensure that material information
relating to the registrants and their consolidated subsidiaries is recorded,
processed , summarized and reported within the time periods specified by the
SEC's rules and forms, particularly during the period in which this quarterly
report has been prepared.

The registrants' principal executive officers and principal financial officer
have concluded that there were no significant changes in the registrants'
internal controls or in other factors that could significantly affect these
controls subsequent to August 31, 2003 the date of their most recent evaluation
of such controls, and that there was no significant deficiencies or material
weaknesses in the registrant's internal controls.

                           PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

As disclosed in the Company's prior filings, the Company is currently Defendant
in an action in the Supreme Court of British Columbia

Management believes that it will be successful in defending against the
Plaintiff's claims. However, if the Plaintiff is successful in his action and
receives the 3,192,399 shares he is seeking, the Company's issued and
outstanding shares will increase and current shareholders would feel an
immediate dilution in the value of their shares. If the Plaintiff is awarded
monetary damages in lieu of the shares, it would have a material adverse effect
on the Company's financial position.

The Company also commenced an action in the Supreme Court of British Columbia on
October 6, 2003. The details of the action are disclosed in the Company's Form
SB-2/A as filed on December 15, 2003.

ITEM 2. CHANGES IN SECURITIES

During the three months ended November 30, 2003, the Company issued the
following unregistered securities:


                                       11
<PAGE>

On October 24, 2003, the Company issued 500,000 share purchase warrants with an
exercise price of $0.50 per share and 500,000 share purchase warrants with an
exercise price of $0.75 for a term of two years. The warrants were issued
pursuant to a Consulting Agreement dated August 22, 2003. The warrants were
issued pursuant to prospectus exemptions contained in Section 4(2) of the
Securities Act of 1933, as amended, and/or Regulation S, and any shares issued
pursuant to the warrants will bear a restrictive Rule 144 legend tot that effect

On November 5, 2003, the Company received a private placement subscription
agreement for 1,000,000 units for a purchase price of $0.35 per unit, each unit
consisting of one common shares and one non transferable share purchase warrant
to purchase an additional share for a price of $0.75 per share until November 5,
2005. The shares were issued pursuant to prospectus exemptions contained in
Section 4(2) of the Securities Act of 1933, as amended, and/or Regulation S, and
will bear a restrictive Rule 144 legend to that effect.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.


ITEM 5.  OTHER INFORMATION

None.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

(a)      Exhibits

3.1      Articles of Incorporation of the Registrant (1)
3.2      By-laws of the Registrant (1)
99.1     Section 906 Certification of CEO
99.2     Section 906 Certification of CFO
99.3     Press Release:  Analyst Coverage and Buy Recommendation, dated
            September 22, 3003 (2)
99.4     Press Release:  Drug Eluting Stent Coating Process, dated September 24,
            2003 (2)
99.5     Press Release:  MIVT on EuroNews TV, dated October 8, 2003 (2)
99.6     Press Release:  MIV Therapeutics Accepted on Frankfurt Stock Exchange,
            dated October 30, 2003 (2)
99.7     Press Release:  MIVT Welcomes Dr. Arun Chockalingam, dated November 4,
            2003 (2)
----------------
         (1)      Previously filed as an Exhibit to MIV Therapeutics, Inc.'s
                  registration statement on Form 10-SB filed April 25, 2000.

         (2)      Previously filed as an Exhibit to the Company's Quarterly
                  Report on Form 10-QSB filed January 14, 2004.

(b) Reports on Form 8-K filed during the three months ended November 30, 2003.

     The Company did not file any current reports on Form 8-K during the three
     months ended November 30, 2003.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

Date:  April 21, 2004                     MIV Therapeutics, Inc.


                                          /s/ Alan Lindsay
                                          ------------------------------
                                          Alan Lindsay
                                          President


                                          /s/ Patrick McGowan
                                          ------------------------------
                                          Patrick McGowan
                                          CFO




                                       13
<PAGE>


CERTIFICATIONS

I, Alan Lindsay, certify that:

1.       I have reviewed this quarterly report on Form 10-QSB of MIV
         Therapeutics, Inc.;

2.       Based on my knowledge, this quarterly report does not contain any
         untrue statement of a material fact or omit to state a material fact
         necessary to make the statements made, in light of the circumstances
         under which such statements were made, not misleading with respect to
         the period covered by this annual report;

3.       Based on my knowledge, the financial statements, and other financial
         information included in this quarterly report, fairly present in all
         material respects the financial condition, results of operations and
         cash flows of the registrant as of, and for, the periods presented in
         this annual report ;

4.       The registrant's other certifying officers and I are responsible for
         establishing and maintaining disclosure controls and procedures (as
         defined in Exchange Act Rules 13a-14 and 15d-14 ) for the registrant
         and have :

         (a)      Designed such disclosure controls and procedures to ensure
                  that material information relating to the registrant,
                  including its consolidated subsidiaries, is made known to us
                  by others within those entities, particularly during the
                  period in which this quarterly report is being prepared;
         (b)      Evaluated the effectiveness of the registrant's disclosure
                  controls and procedures as of a date within 90 days prior to
                  the filing date of this annual report (the "Evaluation date");
                  and
         (c)      Presented in this quarterly report our conclusions about the
                  effectiveness of the disclosure controls and procedures based
                  on our evaluation as of the Evaluation date;

5.       The registrant's other certifying officers and I have disclosed, based
         on our most recent evaluation, to the registrant's auditors and the
         registrant's board of directors:

         (a)      All significant deficiencies in the design or operation of
                  internal controls which could adversely affect the
                  registrant's ability to record, process, summarize and report
                  financial data and have identified for the registrant's
                  auditors any material weaknesses in internal controls, and
         (b)      Any fraud, whether or not material, that involves management
                  or other employees who have a significant role in the
                  registrant's internal controls; and

6.       The registrant's other certifying officers and I have indicated in this
         quarterly report whether there were significant changes in internal
         controls or in other factors that could significantly affect internal
         controls subsequent to the date of our most recent evaluation including
         any corrective actions with regard to significant deficiencies and
         material weaknesses.

Date: April 21, 2004


/s/ Alan Lindsay
-----------------------------
Alan Lindsay
President


                                       14
<PAGE>


I, Patrick McGowan, certify that:

1.       I have reviewed this quarterly report on Form 10-QSB of MIV
         Therapeutics, Inc.;

2.       Based on my knowledge, this quarterly report does not contain any
         untrue statement of a material fact or omit to state a material fact
         necessary to make the statements made, in light of the circumstances
         under which such statements were made, not misleading with respect to
         the period covered by this annual report;

3.       Based on my knowledge, the financial statements, and other financial
         information included in this quarterly report, fairly present in all
         material respects the financial condition, results of operations and
         cash flows of the registrant as of, and for, the periods presented in
         this annual report ;

4.       The registrant's other certifying officers and I are responsible for
         establishing and maintaining disclosure controls and procedures (as
         defined in Exchange Act Rules 13a-14 and 15d-14 ) for the registrant
         and have :

         (a)      Designed such disclosure controls and procedures to ensure
                  that material information relating to the registrant,
                  including its consolidated subsidiaries, is made known to us
                  by others within those entities, particularly during the
                  period in which this quarterly report is being prepared;
         (b)      Evaluated the effectiveness of the registrant's disclosure
                  controls and procedures as of a date within 90 days prior to
                  the filing date of this quarterly report (the "Evaluation
                  date"); and
         (c)      Presented in this annual report our conclusions about the
                  effectiveness of the disclosure controls and procedures based
                  on our evaluation as of the Evaluation date;

5.       The registrant's other certifying officers and I have disclosed, based
         on our most recent evaluation, to the registrant's auditors and the
         registrant's board of directors:

         (a)      All significant deficiencies in the design or operation of
                  internal controls which could adversely affect the
                  registrant's ability to record, process, summarize and report
                  financial data and have identified for the registrant's
                  auditors any material weaknesses in internal controls, and
         (b)      Any fraud, whether or not material, that involves management
                  or other employees who have a significant role in the
                  registrant's internal controls ; and

6.       The registrant's other certifying officers and I have indicated in this
         quarterly report whether there were significant changes in internal
         controls or in other factors that could significantly affect internal
         controls subsequent to the date of our most recent evaluation including
         any corrective actions with regard to significant deficiencies and
         material weaknesses.

Date: April 21, 2004


/s/ Patrick McGowan
---------------------------
Patrick McGowan
CFO



                                       15